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Abstract
Purpose—Approximately 10 percent of the general population have elevated blood 
concentrations of hepatic enzymes, which are linked to increased coagulation markers. We tested 
whether elevated hepatic enzymes are associated with increased risk of venous thromboembolism 
(VTE).
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Methods—We followed prospectively for VTE occurrence 12,604 adults with measurements of 
alanine transaminase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl 
transpeptidase (GGT).
Results—AST and GGT above the laboratory normal were associated over two decades of 
follow-up with increased risk of total (n = 532) and provoked VTE (n = 332), but with not 
unprovoked VTE (n = 200). In a model adjusted for age, race, sex, hormone replacement, alcohol 
intake, diabetes, body mass index, estimated glomerular filtration rate, and C-reactive protein, the 
hazard ratios (95% CI) for high versus normal AST were 1.46 (1.00, 2.11) for total VTE and 1.83 
(1.21, 2.79) for provoked VTE. For high GGT, the hazard ratios were 1.34 (1.06, 1.69) for total 
VTE and 1.43 (1.07, 1.91) for provoked VTE. When follow-up was limited to the first 10-years, 
associations were even stronger (hazard ratios ≈ 1.7 for total VTE).
Conclusion—Elevated concentrations of two hepatic enzymes (AST and GGT) in this general 
middle-aged population are associated with a modestly increased risk of VTE.
Keywords
Venous thrombosis; Pulmonary embolus; Cohort study; Liver enzymes; Risk factors
Introduction
Chronic liver disease has long been considered to carry a high risk of hemorrhage. However, 
recent evidence suggests that decreased plasma coagulation factors are accompanied by 
decreased anticoagulant factors to offset bleeding [1]. Case reports indicate that besides 
portal vein thromboses, cirrhosis patients often develop leg deep vein thrombosis and 
therefore may have a thrombogenic diathesis [2,3]. A large case-control administrative 
database study in Denmark showed a 2-fold elevated venous thromboembolism (VTE) risk 
for both cirrhosis and non-cirrhotic liver disease [4]. Another administrative database study 
showed a modest increased risk of VTE in young (<45 y) cirrhosis patients compared with 
other young inpatients, but no increased risk for VTE in older cirrhosis patients [5]. In a 
nested case-control study in a general practice database, liver disease was associated with a 
1.65 fold increase in VTE risk, but this result was not statistically significant [6]. In contrast 
with the several studies showing a positive association between liver disease and VTE, a 
population based case-control study showed an inverse association between liver disease and 
VTE [7].
More modest hepatic dysfunction than frank liver disease may also relate to VTE risk, but 
solid epidemiologic data are lacking. A recent body mass index (BMI)-matched clinical 
case-control study linked nonalcoholic fatty liver disease with a 2-fold elevated odds of VTE 
[8]. Nonalcoholic fatty liver disease is associated with elevated levels of hepatic enzymes 
[9] and increased levels or activity of several coagulation factor produced in the liver [10]. 
On the other hand, alcohol drinking, which can raise hepatic enzyme levels, generally has 
not been associated or was weakly inversely associated with VTE incidence [11]. Results 
from the National Health and Nutrition Examination Survey (NHANES 2005-2008) indicate 
that elevated hepatic enzymes are highly prevalent in the general population: i.e., elevated 
alanine transaminase (ALT), 10%; aspartate aminotransferase (AST), 16%; and gamma-
Folsom et al. Page 2






















glutamyl transpeptidase (GGT), 9% [12]. Given findings to date and the high prevalence of 
hepatic dysfunction in the population, we prospectively assessed the association between 




The ARIC Study [13] and its methods for identification and classification of VTE have been 
described in detail elsewhere [14,15]. In brief, 15,792 men and women aged 45 to 64 years 
enrolled in the ARIC study in 1987-1989, and had subsequent examinations in 1990-92, 
1993-95, and 1996-98 and annual telephone contact. The present analysis used ARIC visit 2 
as its start point for follow-up, because baseline samples are now scarce. The institutional 
review committees at each study center approved the methods and staff obtained informed 
participant consent.
Measurement of Hepatic Enzymes and VTE Risk Factors
Participants were asked to fast for 12 hours before their morning visit 2 appointments, and 
serum and plasma samples were obtained and stored at −80°C. Soon after the visit, central 
laboratories measured serum creatinine by the Jaffe method and glucose by a hexokinase 
assay. In 2012-13, a number of analytes, including hepatic enzymes, were measured on a 
previously unthawed visit 2 serum aliquot. Hepatic enzymes were measured on the Roche 
Modular P Chemistry analyzer using reagents from Roche Diagnostics (Indianapolis, IN). 
Using duplicate samples collected at visit 2 and stored, we calculated the coefficients of 
variation (CVs), which were 16% for ALT, 6% for AST, and 4% for GGT. This CV 
encompasses variability related to both sample processing and laboratory methods. High 
sensitivity C-reactive protein (hsCRP) was measured using a latex-particle enhanced 
immunoturbidimetric assay kit (Roche Diagnostics) and read on the Roche Modular P 
Chemistry analyzer (CV 7%). Cystatin C was measured using Gentian Cystatin C reagent on 
the Roche Modular P Chemistry analyzer (CV 3%).
Diabetes was defined as a fasting blood glucose of 126 mg/dl or higher, non-fasting blood 
glucose of 200 mg/dl or higher, a physician diagnosis of diabetes, or use of antidiabetic 
medication in the past 2 weeks. Alcohol intake was derived from the usual number of drinks 
of beer, wine, or liquor reported to be consumed per week. Hormone replacement therapy 
(HRT) included estrogen replacement with or without progesterone, identified from pill 
bottles brought to the examination. Glomerular filtration rate (eGFR) was estimated from 
cystatin C and creatinine using the Chronic Kidney Disease Collaboration algorithm [16]. 
Body mass index was calculated as weight (kg)/height (m)2. Factor VIII and activated 
partial thromboplastin time (aPTT) were available from the 1987-9 ARIC baseline visit 
[17,18].
VTE Occurrence
ARIC participants were contacted annually by phone and asked about all hospitalizations in 
the previous year. Hospital records with discharge diagnoses for possible VTE events, based 
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on a broad set of ICD-9CM discharge codes [14], were obtained from baseline through 
2011. To validate the VTE events, two physicians (ARF, MC) reviewed the records using 
standardized criteria [14]. A diagnosis of deep vein thrombosis (DVT) or pulmonary 
embolism (PE) required positive imaging tests. We restricted DVTs for this analysis to those 
in the lower extremity or vena cava, because the vast majority of upper extremity DVTs 
were the result of in-dwelling catheters. Cases were classified by the reviewers as 
unprovoked (no obvious cause) or provoked (associated with recent hospitalization; cancer; 
major trauma; surgery; or marked immobility, such as being bed-ridden or having a fixed 
orthopedic cast).
Statistical Analysis
Of the 14,348 participants at ARIC visit 2, we successively excluded those who did not have 
any hepatic enzymes measured (n = 975), had a prior VTE (n = 260), were taking 
anticoagulants (n = 95), had heavy alcohol use (men >21 drinks/wk, women >14 drinks/wk) 
(n = 374), were not white or African American (n = 37), or had no follow-up after visit 2 (n 
= 3). (Those excluded for heavy alcohol use were 2-3 times as likely to have elevated 
hepatic enzyme concentrations.) This left 12,604 participants for the present analyses of 
incident VTE in relation to hepatic enzyme concentrations. Hepatic enzyme distributions 
were skewed and preliminary cubic spline graphs suggested non-linearity in relation to VTE. 
The enzymes therefore were analyzed as categories: (a) 5 categories with cutpoints at 25, 50, 
75, and 90th percentiles of the whole distribution, (b) high/low based on the sex-specific 
upper limit cutpoints (in U/L) for normal ranges for the assays in our laboratory: ALT 
(women: 31, men: 41), AST (women: 31, men: 37), and GGT (women: 36, men: 61). Time 
at risk for VTE was computed from the date of visit 2 to the earliest of the following: date of 
hospital discharge with incident VTE, date of death, date of last follow-up contact, or end of 
follow-up.
Our main hypothesis was that hepatic enzyme levels would be associated positively with 
VTE incidence. Cox proportional hazards models were used to calculate hazard ratios (HR) 
and 95% confidence intervals of incident VTE. We verified the proportional hazards 
assumption of the Cox models by inspection of ln(-ln) survival curves for hepatic enzyme 
categories. We selected possible confounding variables for regression models based on our 
previous prospective findings on VTE risk factors [15,17,18]. Model 1 adjusted for age 
(continuous), sex, and race (African American, white); Model 2 for age, race, sex/HRT 
(men, women using HRT, women not using HRT), alcohol intake (continuous), diabetes 
status (yes or no), body mass index, eGFR and CRP (all continuous). Model 3 included two 
potential mediators, Factor VIII and aPTT (both continuous), from visit 1.
We also conducted three independent sensitivity analyses. Firstly, we removed from analysis 
VTE cases in the first three years of follow-up, in case these early cases were unusual. 
Secondly, we removed from analyses participants with obesity (BMI > 30 kg/m2) at 
baseline, because we considered obese participants most likely to have non-alcoholic fatty 
liver disease. Thirdly, we truncated follow-up to 10 years, because hepatic enzyme levels at 
baseline would become less relevant during late follow-up.
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Among the 12,604 ARIC participants in this analysis, the median values (in U/L) for ALT, 
AST, and GGT were 14, 20, and 21, and the percentage with values above the upper limits 
of normal were 3%, 4%, and 13%, respectively. The Spearman correlation coefficient 
between ALT and AST was r = 0.63, between ALT and GGT was r = 0.45, and between 
AST and GGT was r = 0.33.
Table 1 shows participant characteristics according to sex-specific high versus normal 
hepatic enzyme categories. Using GGT as an example, participants with high GGT levels 
were more often African American, nonusers of HRT (in women), and diabetic, had higher 
mean values of BMI, CRP, and factor VIII, and shorter aPTT. Even though heavy alcohol 
users were excluded, average alcohol intake was higher in those with high GGT. On average 
those with high GGT drank 4.5 drinks per week, versus 3.3 drinks per week for those with 
normal GGT. With a few exceptions, findings were generally similar for ALT and AST.
VTE Incidence Across the Range of Hepatic Enzymes
Over a median of 20 years of follow-up, 532 incident lower extremity DVTs and/or PEs 
occurred, of which 200 were unprovoked. As shown in Table 2 for Model 2 and 
Supplemental Table 1 for all models, hepatic enzyme levels across the full range showed 
little association with VTE incidence. Compared with the first quartile (reference), hazard 
ratios for the middle quartiles and highest group of hepatic enzymes tended to be the same 
or slightly lower. For example, the Model 2 hazard ratios (95% CI) for VTE in relation to 
GGT categories were 1 (reference), 0.76 (0.58, 1.01), 0.91 (0.69, 1.21), 1.02 (0.75, 1.39), 
and 1.15 (0.82, 1.62). When VTE was stratified into unprovoked versus provoked, neither 
VTE type showed a significant adjusted association with ALT, AST, or GGT percentile 
groupings (data not shown).
VTE Incidence for High Versus Low Hepatic Enzymes
In contrast, when analyzed as abnormal (high) versus normal (Table 3 and Supplemental 
Table 2), high AST and GGT levels were associated with increased incidence of total and 
provoked VTE, though not unprovoked VTE. The Model 2 hazard ratios (95% CI) for high 
versus normal AST were 1.46 (1.00, 2.11) for total VTE and 1.83 (1.21, 2.79) for provoked 
VTE. For high GGT, the hazard ratios were 1.34 (1.06, 1.69) for total VTE and 1.43 (1.07, 
1.91) for provoked VTE. These associations persisted after adjustment for aPTT and factor 
VIII (Model 3).
A supplemental analysis removing n = 27 VTEs occurring in the first three years of follow-
up had little impact on the Model 2 hazard ratios in Table 3 (data not shown). In contrast, 
truncating follow-up to a maximum of 10 years (leaving n = 134 incident VTEs) 
strengthened the associations but widened the confidence intervals due to fewer events 
(Table 3). For example, the Model 2 hazard ratios (95% CI) for high versus normal AST 
through the first 10 years of follow-up were 1.74 (0.88, 3.44) for total VTE, 2.30 (1.05, 
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5.07) for provoked VTE, and 0.93 (0.22, 3.82) for unprovoked VTE. For high GGT, these 
respective hazard ratios were 1.70 (1.09, 2.65), 1.81 (1.03, 3.19), and 1.57 (0.77, 3.20).
In a sensitivity analysis restricting to participants without obesity (BMI < 30 kg/m2) and 
leaving n = 307 VTEs (data not shown), the hazard ratios also were somewhat stronger than 
for Table 3. For example, the Model 2 hazard ratios (95% CI) for high versus normal AST in 
nonobese participants were 2.11 (1.33, 3.34) for total VTE and 2.55 (1.49, 4.36) for 
provoked VTE. For high GTT, these hazard ratios were 1.60 (1.16, 2.21) and 1.63 (1.09, 
2.44), respectively.
Association of VTE Incidence with Alcohol Intake
Alcohol intake was weakly positively associated with total and provoked VTE incidence but 
not unprovoked VTE. In Model 2 but without hepatic enzymes in the model, the hazard 
ratios (95% CI) per 75 g/wk increment of alcohol intake were 1.15 (1.02, 1.29) for total 
VTE and 1.22 (1.06, 1.41) for provoked VTE. Adding any of the three hepatic enzymes to 
this model attenuated these alcohol hazard ratios only slightly (data not shown).
Discussion
In this prospective population based cohort, participants with values of GGT and AST above 
the normal range had 34 and 46 percent greater incidence of VTE over two decades of 
follow-up than did normal participants. The associations were stronger when follow-up was 
restricted to 10 years (70% and 74% increased 10-year risk for high AST and high GGT). 
The associations were independent of several VTE risk factors, and it was due to greater risk 
of provoked VTEs, rather than unprovoked. Within the normal range, higher values of 
hepatic enzymes did not increase VTE risk.
The precise reasons for individual participants having high GGT or AST are unknown. We 
excluded the heavy alcohol drinkers to remove this potential source of confounding, but 
self-reported alcohol intake is known to be somewhat misclassified. Even with the 
exclusion, hepatic enzyme levels remained positively associated with alcohol intake, and 
associated with most other measured VTE risk factors (Table 1 and Supplemental Table 1). 
However, we adjusted for all of these factors, including alcohol, which itself was weakly 
positively associated with VTE risk, in contrast with most previous epidemiologic studies of 
alcohol and VTE [11].
ARIC did not have information to exclude medical conditions that might have caused 
elevations in visit 2 hepatic enzyme levels, such as cirrhosis or metastatic cancer. However, 
most of these are rare in a general population cohort. A significant proportion of elevated 
values not due to alcohol might be expected to be from nonalcoholic fatty liver disease 
[9,19]. Previous studies of VTE and diagnoses of severe liver disease [4-7] or nonalcoholic 
fatty liver disease [8] have generally shown positive associations with VTE risk, but not 
uniformly. Arguing against nonalcoholic fatty liver disease being the link between elevated 
hepatic enzymes and VTE in this cohort is the fact that the association was stronger after 
removing participants with obesity, who are most likely to have nonalcoholic fatty liver 
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disease. Additionally, the associations observed between ALT, the most liver specific 
enzyme, and VTE were all null.
Elevated hepatic enzyme values are certainly not a “cause” of VTE, but mild hepatic 
dysfunction may increase production of cytokines and coagulation factors, leading to a 
thrombotic diathesis. Nonalcoholic fatty liver disease is associated with increased levels or 
activity of several coagulation factors [10]. In our study, higher GGT was associated with 
higher factor VIII and shorter aPTT, which are both VTE risk markers [17,18]. Adjustment 
for factor VIII and aPTT did not explain the association of high AST and GGT with 
increased VTE risk, but this may not be surprising, as the hemostasis markers were 
measured three years before the blood for hepatic function tests.
High AST and GGT were associated with provoked VTEs only, which included 62 percent 
of all VTEs. The designation of “provoked” was assigned by the study physicians 
adjudicating the VTE events, who were masked to the hepatic enzyme values. It was defined 
as VTE due to recent hospitalization, cancer, major trauma, surgery, or marked immobility 
[14], but not conditions like obesity, hormone replacement therapy, or short plane or car 
rides. VTEs without obvious precipitants defined as “unprovoked,” but of course a 
triggering factor may not have been documented in the medical record. Because the 
provoking conditions were at the time of VTE, up to 18 years after hepatic function 
assessment, it is unlikely that the provoking factors, unless longstanding, caused the elevated 
AST or GGT. A previous analysis in an earlier set of VTEs showed that most baseline 
characteristics examined were similar between provoked and unprovoked VTE, except for a 
somewhat greater history of cancer at baseline in those who later had a provoked VTE (13% 
versus 10% for unprovoked) [14]. Those with elevated baseline AST or GGT may have been 
more likely over the ensuing years to have developed medical conditions leading to VTE. 
Thus, the argument that hepatic dysfunction leads to VTE in a causal fashion is weakened 
by the absence of an association with unprovoked VTE. However, statistical power was less 
for unprovoked VTE, which was rarer than provoked VTE. Nevertheless, irrespective of the 
causal pathways, elevated AST or GGT does mark a small group of middle-aged adults at 
increased VTE risk.
Some other methodologic aspects of this study warrant consideration. Firstly, being a cohort 
study, we documented that elevated AST and GGT preceded VTE onset. However, we had 
only a single measurement and over the long follow-up period participants may have 
changed between high versus normal categories. Such misclassification typically would 
weaken the observed association between AST and GGT, so the real association may be 
stronger as evidenced by the sensitivity analysis restricted to 10 years of follow-up. 
Secondly, samples were stored unthawed at −80°C for two decades prior to measurement of 
hepatic enzyme levels. At −80°C, AST is stable at least two years [20]. We also found 
hepatic enzymes associated as expected with alcohol intake, sex, and other factors. Any 
deterioration in the freezer would most likely bias hazard ratios toward the null. Thirdly, the 
prevalence of elevated hepatic function tests was lower in ARIC than reported by NHANES 
[12]. This might be explained by differences in study date (ARIC 1990-92 vs. NHANES 
2005-8); differences in the prevalence of obesity; ARIC’s exclusion of individuals with 
heavy alcohol consumption; or different laboratory reference values for elevated hepatic 
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enzymes. In the absence of a standard definition of “elevated” hepatic enzymes, ARIC used 
the cut-off provided by the manufacturer of the assay. It has been documented the range of 
upper limits of normal for hepatic enzymes can vary widely [21]. Nevertheless, it seems 
unlikely that these differences between ARIC and NHANES would affect the internal 
validity of ARIC’s findings. Finally, only hospitalized VTE events were captured; yet, 
several pilot studies in ARIC have suggested that the vast majority of initial VTEs are 
hospitalized.
In conclusion, elevated levels of AST and GGT in this general middle-aged population are 
associated with a modestly increased risk of VTE over the next two decades.
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• Concentrations of hepatic enzymes are often elevated in the general population.
• Whether this increases risk venous thromboembolism (VTE) risk is unknown.
• We found elevated concentrations of two hepatic enzymes (AST and GGT) 
associated with a 40% increased VTE incidence.
• Patients with elevated hepatic enzymes warrant consideration for thrombosis 
risk.
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